NO309455B1 - Filmbelagt tablett av paracetamol og domperidon - Google Patents
Filmbelagt tablett av paracetamol og domperidon Download PDFInfo
- Publication number
- NO309455B1 NO309455B1 NO962153A NO962153A NO309455B1 NO 309455 B1 NO309455 B1 NO 309455B1 NO 962153 A NO962153 A NO 962153A NO 962153 A NO962153 A NO 962153A NO 309455 B1 NO309455 B1 NO 309455B1
- Authority
- NO
- Norway
- Prior art keywords
- tablet
- domperidone
- tablet according
- paracetamol
- tablets
- Prior art date
Links
- 229960001253 domperidone Drugs 0.000 title claims abstract description 30
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 title claims abstract description 30
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 229960005489 paracetamol Drugs 0.000 title claims abstract description 28
- 239000007941 film coated tablet Substances 0.000 title abstract description 7
- 239000003826 tablet Substances 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 17
- 239000007888 film coating Substances 0.000 claims description 15
- 238000009501 film coating Methods 0.000 claims description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 11
- 229920002261 Corn starch Polymers 0.000 claims description 9
- 239000008120 corn starch Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 206010027599 migraine Diseases 0.000 claims description 8
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 229920000881 Modified starch Polymers 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- OAUUYDZHCOULIO-BTJKTKAUSA-N domperidone maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.O=C1[NH2+]C2=CC=CC=C2N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2[NH2+]C1=O OAUUYDZHCOULIO-BTJKTKAUSA-N 0.000 claims description 6
- 229960004268 domperidone maleate Drugs 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000000454 talc Substances 0.000 claims description 6
- 229910052623 talc Inorganic materials 0.000 claims description 6
- 239000003979 granulating agent Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 3
- 239000001692 EU approved anti-caking agent Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 238000007580 dry-mixing Methods 0.000 claims description 2
- -1 flow improvers Substances 0.000 claims description 2
- 239000006069 physical mixture Substances 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 230000009747 swallowing Effects 0.000 claims description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 229940125683 antiemetic agent Drugs 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 229940099112 cornstarch Drugs 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005461 lubrication Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229920003125 hypromellose 2910 Polymers 0.000 description 1
- 229940031672 hypromellose 2910 Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940063002 magnesium palmitate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dental Preparations (AREA)
- Piezo-Electric Or Mechanical Vibrators, Or Delay Or Filter Circuits (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94200498 | 1994-02-28 | ||
| PCT/EP1995/000719 WO1995022974A2 (en) | 1994-02-28 | 1995-02-27 | Film coated tablet of paracetamol and domperidone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO962153D0 NO962153D0 (no) | 1996-05-28 |
| NO962153L NO962153L (no) | 1996-08-26 |
| NO309455B1 true NO309455B1 (no) | 2001-02-05 |
Family
ID=8216670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO962153A NO309455B1 (no) | 1994-02-28 | 1996-05-28 | Filmbelagt tablett av paracetamol og domperidon |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5814339A (cs) |
| EP (1) | EP0749308B1 (cs) |
| JP (1) | JP2931409B2 (cs) |
| KR (1) | KR100202154B1 (cs) |
| CN (1) | CN1084616C (cs) |
| AT (1) | ATE240102T1 (cs) |
| AU (1) | AU703242B2 (cs) |
| BR (1) | BR9506903A (cs) |
| CA (1) | CA2182004C (cs) |
| CY (1) | CY2383B1 (cs) |
| CZ (1) | CZ291999B6 (cs) |
| DE (1) | DE69530759T2 (cs) |
| DK (1) | DK0749308T3 (cs) |
| ES (1) | ES2199982T3 (cs) |
| FI (1) | FI117373B (cs) |
| HU (1) | HU228149B1 (cs) |
| IL (1) | IL112802A (cs) |
| MX (1) | MX9603690A (cs) |
| MY (1) | MY115433A (cs) |
| NO (1) | NO309455B1 (cs) |
| NZ (1) | NZ281236A (cs) |
| PL (1) | PL179080B1 (cs) |
| PT (1) | PT749308E (cs) |
| RU (1) | RU2153337C2 (cs) |
| SI (1) | SI0749308T1 (cs) |
| SK (1) | SK282506B6 (cs) |
| TW (1) | TW466119B (cs) |
| WO (1) | WO1995022974A2 (cs) |
| ZA (1) | ZA951616B (cs) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9710767D0 (en) * | 1996-06-26 | 1997-07-23 | On Ninh | Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same |
| GB9702392D0 (en) * | 1997-02-06 | 1997-03-26 | Boots Co Plc | Therapeutic agents |
| GB9816899D0 (en) | 1998-08-05 | 1998-09-30 | Boots Co Plc | Therapeutic agents |
| US20030072731A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing starch or dextrin |
| US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| RU2266744C2 (ru) * | 2001-06-21 | 2005-12-27 | Duchesnay Ink. | Композиция быстрого начала действия |
| US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
| RU2192848C1 (ru) * | 2001-10-30 | 2002-11-20 | Закрытое акционерное общество "ВЕРОФАРМ" | Противорвотное средство |
| US7429619B2 (en) | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
| RU2268047C2 (ru) * | 2003-12-15 | 2006-01-20 | Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" | Лекарственная форма, обладающая противорвотным действием, и способ ее изготовления |
| GB2443793B (en) * | 2006-04-05 | 2010-12-01 | Reckitt Benckiser Healthcare | Product, method of manufacture and use |
| WO2008134540A1 (en) * | 2007-04-26 | 2008-11-06 | Aronchick Craig A | Compositions and methods for transmucosal delivery of domperidone |
| US20090060983A1 (en) * | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
| WO2009058798A2 (en) | 2007-10-31 | 2009-05-07 | Mcneil-Ppc, Inc. | Orally disintegrated dosage form |
| US20110318411A1 (en) | 2010-06-24 | 2011-12-29 | Luber Joseph R | Multi-layered orally disintegrating tablet and the manufacture thereof |
| US8871263B2 (en) * | 2009-09-24 | 2014-10-28 | Mcneil-Ppc, Inc. | Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder |
| US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
| US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
| US9233491B2 (en) | 2012-05-01 | 2016-01-12 | Johnson & Johnson Consumer Inc. | Machine for production of solid dosage forms |
| FR2992218B1 (fr) * | 2012-06-22 | 2015-01-23 | Rivopharm Sa | Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation |
| CA2936216C (en) | 2014-01-10 | 2021-10-26 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
| CA3013123A1 (en) * | 2016-02-04 | 2017-08-10 | Cinrx Pharma, Llc | Deuterated domperidone compositions and methods for therapy of disorders |
| US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
| KR20240125702A (ko) | 2017-06-30 | 2024-08-19 | 신돔 파마, 인크. | 중수소화 돔페리돈 조성물, 방법, 및 제조 |
| CN110302169A (zh) * | 2019-08-01 | 2019-10-08 | 张慧芬 | 一种滑膜衣片剂及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU528098B2 (en) * | 1978-11-16 | 1983-04-14 | Beecham Group Plc | Analgesic tablet |
| CA2020018A1 (en) * | 1990-06-27 | 1991-12-28 | Don L. Simmons | Method and composition for treating the migraine complex |
| MX9300110A (es) * | 1992-01-13 | 1994-07-29 | Gerhard Gergely | Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion. |
| CA2139638A1 (en) * | 1992-07-07 | 1994-01-20 | Nancy M. Gray | Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders |
| RU2068689C1 (ru) * | 1992-09-24 | 1996-11-10 | Товарищество с ограниченной ответственностью "Лекрон" | Способ получения таблеток парацетамола |
| TW272942B (cs) * | 1993-02-10 | 1996-03-21 | Takeda Pharm Industry Co Ltd | |
| RU2034533C1 (ru) * | 1993-02-25 | 1995-05-10 | Химико-фармацевтическое акционерное общество открытого типа "Октябрь" | Анальгезирующее жаропонижающее лекарственное средство и способ его получения |
-
1995
- 1995-02-24 TW TW084101709A patent/TW466119B/zh not_active IP Right Cessation
- 1995-02-27 RU RU96111912/14A patent/RU2153337C2/ru active
- 1995-02-27 ES ES95909789T patent/ES2199982T3/es not_active Expired - Lifetime
- 1995-02-27 CN CN95191736A patent/CN1084616C/zh not_active Expired - Lifetime
- 1995-02-27 KR KR1019960702874A patent/KR100202154B1/ko not_active Expired - Lifetime
- 1995-02-27 MY MYPI95000497A patent/MY115433A/en unknown
- 1995-02-27 CA CA002182004A patent/CA2182004C/en not_active Expired - Lifetime
- 1995-02-27 PL PL95314850A patent/PL179080B1/pl unknown
- 1995-02-27 NZ NZ281236A patent/NZ281236A/en not_active IP Right Cessation
- 1995-02-27 ZA ZA951616A patent/ZA951616B/xx unknown
- 1995-02-27 BR BR9506903A patent/BR9506903A/pt not_active IP Right Cessation
- 1995-02-27 EP EP95909789A patent/EP0749308B1/en not_active Expired - Lifetime
- 1995-02-27 DK DK95909789T patent/DK0749308T3/da active
- 1995-02-27 JP JP7522147A patent/JP2931409B2/ja not_active Expired - Lifetime
- 1995-02-27 CZ CZ19962255A patent/CZ291999B6/cs not_active IP Right Cessation
- 1995-02-27 AU AU18123/95A patent/AU703242B2/en not_active Expired
- 1995-02-27 MX MX9603690A patent/MX9603690A/es unknown
- 1995-02-27 WO PCT/EP1995/000719 patent/WO1995022974A2/en active IP Right Grant
- 1995-02-27 PT PT95909789T patent/PT749308E/pt unknown
- 1995-02-27 HU HU9601384A patent/HU228149B1/hu unknown
- 1995-02-27 IL IL11280295A patent/IL112802A/xx not_active IP Right Cessation
- 1995-02-27 SI SI9530668T patent/SI0749308T1/xx unknown
- 1995-02-27 US US08/652,514 patent/US5814339A/en not_active Expired - Lifetime
- 1995-02-27 AT AT95909789T patent/ATE240102T1/de active
- 1995-02-27 DE DE69530759T patent/DE69530759T2/de not_active Expired - Lifetime
- 1995-02-27 SK SK1032-96A patent/SK282506B6/sk not_active IP Right Cessation
-
1996
- 1996-05-22 FI FI962156A patent/FI117373B/fi not_active IP Right Cessation
- 1996-05-28 NO NO962153A patent/NO309455B1/no not_active IP Right Cessation
-
2003
- 2003-11-04 CY CY0300078A patent/CY2383B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO309455B1 (no) | Filmbelagt tablett av paracetamol og domperidon | |
| JP4744142B2 (ja) | ラモトリギンを含む徐放性処方 | |
| JP5948648B2 (ja) | 安定化されたエペリゾンを含有する徐放性製剤 | |
| US20050158380A1 (en) | Sustained release oral dosage forms of gabapentin | |
| WO2011001202A1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
| WO2014209087A1 (en) | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin | |
| KR100846945B1 (ko) | 파라세타몰을 포함하는 연하 정제 | |
| EP2063862A2 (en) | Pharmaceutical formulation for use in hiv therapy | |
| WO2006123213A1 (en) | Modified release formulations of gliclazide | |
| WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
| MXPA05002136A (es) | Forma de dosificacion de liberacion controlada de nitrofurantoina. | |
| CA2458776A1 (en) | Controlled release formulation of clarithromycin or tinidazol | |
| CN111346066A (zh) | 含吡拉西坦的缓释制剂 | |
| WO2007003746A1 (fr) | Formulation a liberation prolongee de principes actifs presentant une solubilite dependante du ph | |
| JPWO2003075919A1 (ja) | 塩酸ピルジカイニド含有錠剤（乾式） | |
| US20230201123A1 (en) | Pharmaceutical composition | |
| JP2021518424A (ja) | 様々な用量のレナリドミドの経口用錠剤組成物 | |
| HK1010687B (en) | Film coated tablet of paracetamol and domperidone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |